ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "rheumatoid arthritis"

  • Abstract Number: 0070 • ACR Convergence 2025

    Integrating Synovial Protein Signatures and Serum Profiles to Predict Disease Activity and Treatment Response in Early Rheumatoid Arthritis

    Chary López pedrera1, Sagrario Corrales2, Julio Osuna3, Rafaela Ortega-Castro4, Jerusalén Calvo5, Lourdes Ladehesa6, Ismael Sanchez-Pareja2, Laura muñoz-Barrera2, Desiree Ruiz-Vilchez7, Christian Merlo8, MARIA ANGELES AGUIRRE ZAMORANO2, Nuria Barbarroja9, Tomás Cerdó2, Marta Alarcon-Riquelme10, Carlos Pérez Sánchez11, Alejandro Escudero Contreras5 and Concepción Aranda-Valera5, 1Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Spain, 2Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Spain, 3IMIBIC/Reina Sofia Hospital/University of Cordoba, Spain., Córdoba, Republic of Korea, 4Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Andalucia, Spain, 5IMIBIC / Reina Sofia Hospital / University of Cordoba, Córdoba, Spain, 6IMIBIC-Reina Sofia Hospital-University of Cordoba, Cordoba, Spain, Cordoba, Spain, 7Department of Rheumatology, Reina Sofía University Hospital / Maimonides Institute for Biomedical Research of Córdoba (IMIBIC) / Department of Medical and Surgical Sciences, Faculty of Medicine, University of Córdoba, Spain, Cordoba, Spain, 8Rheumatology Service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/University of Cordoba/ Reina Sofia University Hospital, Córdoba, Spain, Cordoba, Spain, 9Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain, 10Fundación Progreso y Salud, Andalusian Government, Granada, Spain, 11Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/ CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain

    Background/Purpose: The analysis of synovial tissue has been instrumental in advancing our understanding of Rheumatoid Arthritis (RA) pathogenesis. As an alternative, the identification of serum…
  • Abstract Number: 0045 • ACR Convergence 2025

    Genetic regulators of corticosteroid response in hepatic and adipose tissue and risk of adverse metabolic outcomes in patients with rheumatoid arthritis initiating glucocorticoids.

    Thomas Riley1, Bryant England2, Austin Wheeler2, Punyasha Roul3, Grant Cannon4, Brian Sauer5, Gary Kunkel6, Katherine Wysham7, Beth Wallace8, Andreas Reimold9, Gail Kerr10, Isaac Smith11, John Richards12, Iris Lee13, Mitchell Lazar1, Wenxiang Hu14, Michael Levin15, Scott Damrauer15, Rui Xiao16, Tate Johnson2, Ted Mikuls2, Joshua Baker1 and Michael George1, 1University of Pennsylvania, Philadelphia, PA, 2University of Nebraska Medical Center, Omaha, NE, 3UNMC, Omaha, NE, 4University of Utah and Salt Lake City VA, Salt Lake City, UT, 5Salt Lake City VA/University of Utah, Salt Lake City, UT, 6University of Utah and George E Wahlen VAMC, Salt Lake City, UT, 7VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, 8Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, 9Dallas VA Medical Center, Dallas, TX, 10Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, 11Duke University Hospital, Durham, NC, 12Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA, 13Washington University in St Louis, Saint Louis, MO, 14Guangzhou National Laboratory, Guangzhou, China (People's Republic), 15University of Pennsylvania / Corporal Michael J. Crescenz VAMC, Philadelphia, PA, 16Children's Hospital of Philadelphia, Philadelphia, PA

    Background/Purpose: Previous studies identified single nucleotide polymorphisms (SNPs) that affect hepatocyte and adipocyte response to glucocorticoids (GCs). We aimed to determine if these candidate SNPs…
  • Abstract Number: L10 • ACR Convergence 2024

    Neuroimmune Modulation in Adults with Rheumatoid Arthritis and Inadequate Response or Intolerance to Biological or Targeted Synthetic DMARDs: Results at 12 and 24 Weeks from a Randomized, Sham-Controlled, Double-Blind Pivotal Study

    John Tesser1, Joshua June2, Pendleton Wickersham3, Jane Box4, Guillermo Valenzuela5, Angela Crowley6, Nikila Kumar7, Norman Gaylis8, Gordan Lam9, David Ridley10, Gineth Paola Pinto-Patarroyo11 and David Chernoff12, 1Arizona Arthritis & Rheumatology Associates, Phoenix, AZ, 2Great Lakes Center of Rheumatology, Lansing, MI, 3Arthritis Associates PA, San Antonio, TX, 4DJL Clinical Research, PLLC, Charlotte, NC, 5Guillermo Valenzuela MD PA/ IRIS Rheumatology, Plantation, FL, 6Illinois Bone and Joint Institute - Hinsdale Orthopaedics, Hinsdale, IL, 7Arizona Arthritis & Rheumatology Associates, Scottsdale, AZ, 8Arthritis & Rheumatic Disease Specialties, Aventura, FL, 9Arthritis & Osteoporosis Consults of the Carolinas, Charlotte, NC, 10St. Paul Rheumatology, Eagan, MN, 11Annapolis Rheumatology, Fairfax, VA, 12SetPoint Medical, Sausalito, CA

    Background/Purpose: In this study, we evaluated the safety and efficacy of an implantable, cervical vagus nerve stimulation device for treatment of RA. Methods: This randomized,…
  • Abstract Number: L12 • ACR Convergence 2024

    A-319, a CD3 X CD19 T Cell Engager (TCE), for the Treatment of Severe/Refractory SLE: Early Evidence of Rapid Reset of Disease-Specific Autoimmunity

    Chunli Mei1, Xin Guan1, Bin Wu2, Mengjiao Li1, Xiaojing Liu1, Xi Chen1, You Song1, Weiwei Wang1, Cheng Wang1, Huiling Mei1, Xiaoru Duan1, Lijuan Jiang1, Wenlin Qiu1, Likai Yu1, Yuhong Liu1, Xing Zhao3, Xuanfan Zhong3, Shengjie Xue3, Wuzhong Shen3, Ying Tan3, Guojian Yu3, Guiyun Tu3, Hanyang Chen3, Amy Sun3, Xiaoqiang Yan3, Anbing Huang1, Rong Du1 and Qiubai Li1, 1Department of Rheumatology and Immunology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, 2Department of Rheumatology and Immunology of the First People’s Hospital of Jingzhou, Jingzhou, China, 3ITabMed Ltd. Changchun, Shanghai, China

    Background/Purpose: CD19 CAR T treatment has demonstrated clinical benefits to patients with severe/refractory systemic lupus erythematosus (SLE), possibly due to resetting autoimmunity. A-319, a highly…
  • Abstract Number: L20 • ACR Convergence 2024

    Automated Ultrasound System ARTHUR with AI Analysis DIANA Matches Expert Rheumatologist in Hand Joint Assessment of Rheumatoid Arthritis Patients

    Bill Aplin Frederiksen1, Mads Ammitzbøll Danielsen2, Hilde Berner Hammer3, Benjamin Schultz Overgaard1, Anders Weber4, Lene Terslev2, Thiusius Rajeeth Savarimuthu5 and Soren Andreas Just1, 1Section of Rheumatology, Department of Medicine, Svendborg Sygehus OUH, Svendborg, Denmark, 2Center for Rheumatology and Spine Disease, Rigshospitalet, Glostrup, Denmark, 3Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, Faculty of Medicine, University of Oslo, Oslo, Norway, 4ROPCA, Odense, Denmark, 5Mærsk Mc-Kinney Møller Institute, University of Southern Denmark, Odense, Denmark

    Background/Purpose: To evaluate the precision of ARTHUR (Figure 1), a CE-marked, fully automated ultrasound scanning system that captures ultrasound images of 22 hand joints and…
  • Abstract Number: 0034 • ACR Convergence 2024

    Arthritogenic Subdoligranulum (S. Dido 7) Is Increased in Individuals At-Risk for and with Early RA and Decreases over Time During Development of Inflammatory Arthritis

    Lyndsey Cole1, Sucai Liu2, Brendan Allen2, Marie Feser3, Kristen Demoruelle4, Kevin Deane5, Michael Holers3 and Kristine Kuhn6, 1University of Colorado School of Medicine, Centennial, CO, 2University of Colorado School of Medicine, Aurora, CO, 3Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, 4University of Colorado Anschutz Medical Campus, Golden, CO, 5University of Colorado Denver Anschutz Medical Campus, Aurora, CO, 6University of Colorado, Aurora, CO

    Background/Purpose: Subdoligranulum didolesgii, S. dido 7, is present in a subset of individuals who are at-risk for RA (termed ‘ARI’) and who have clinical RA,…
  • Abstract Number: 0051 • ACR Convergence 2024

    Impact of Tight Junction Proteins on Inflammatory Processes and Microbial Imbalance in Rheumatoid Arthritis

    Arkaitz Mucientes1, jose Manuel Lisbona-Montañez2, Patricia Ruiz-Limón3, Sara Manrique-Arija4, Aimara García-Studer4, Fernando Ortiz-Márquez4, Natalia Mena Vázquez5 and Antonio Fernández-Nebro6, 1IBIMA Plataforma BIONAND, Malaga, Andalucia, Spain, 2University of Malaga, Malaga, Andalucia, Spain, 3IBIMA, Instituto de Biomedicina de Málaga, Cordoba, Spain, 4Biomedical Research Institute of Malaga (IBIMA)-Bionand Platform, Department of Rheumatology, Regional University Hospital of Malaga, Malaga, Spain, 5IBIMA, Málaga, Andalucia, Spain, 6Department of Rheumatology, Hospital Universitario de Málaga, Málaga, Andalucia, Spain

    Background/Purpose: The etiology of Rheumatoid Arthritis (RA) is not fully understood. Recent studies point to intestinal permeability as an important factor in the establishment and…
  • Abstract Number: 0087 • ACR Convergence 2024

    SYNCAR: An Engineered IL-2/IL-2R-system That Selectively Enhances CD19 CAR T Cells to Deplete B Cells and Provide Therapeutic Benefit in SLE and RA Mouse Models Without Lymphodepletion

    Ethan Jung1, Marie semana1, Ivan Cheng1, Helena Silva1, Sandro Vivona1, Somya Singh1, Michele Bauer1, Mohammed Ali1, Henry Rosas1, Woei Chang1, Deepti Rokkam1, Patrick Lupardus1, Martin Oft1 and Paul-Joseph Aspuria2, 1Synthekine, Menlo Park, 2Sythekine, Menlo Park, CA

    Background/Purpose: CD19 CAR-T therapy has demonstrated efficacy in autoimmune (AI) diseases like systemic lupus erythematosus (SLE) and lupus nephritis (LN), showing its potential beyond oncology.…
  • Abstract Number: 0202 • ACR Convergence 2024

    Survival in Patients with Rheumatoid Arthritis and Early-Stage Colorectal, Lung, or Prostate Cancer Receiving Tumor Necrosis Factor Alpha Inhibitors

    Maria Suarez-Almazor1, Juan Ruiz2, Xiudong Lei1, Hui Zhao1, Suja Rajan3, Heather Lin1 and Sharon Giordano1, 1MD Anderson Cancer Center, Houston, TX, 2MD Anderson, Houston, TX, 3The University of Texas Health Science Center at Houston, Houston, TX

    Background/Purpose: There is concern about the use of tumor necrosis factor inhibitors (TNFi) in patients with early cancer given their immunosuppressant effects. Few studies have…
  • Abstract Number: 0310 • ACR Convergence 2024

    I-CARE Program: Interest of Multidisciplinary Systematic Screening Program for Comorbidities for Patients Suffering from Arthritis Rheumatoid DiseasE: A Real Life Study

    Amine Mouamnia, Armentieres Hospital Center, Armentieres, France

    Background/Purpose: Inflammatory and auto-immune disease are associated to comordities. Indeed, patients suffering from arthritis rheumatoid disease (ARD) such as rheumatoid arthritis (RA), polymyalgia rheumatica (PMR)…
  • Abstract Number: 0449 • ACR Convergence 2024

    Evaluating Premenstrual Dysphoric Disorder in Women with Rheumatoid Arthritis and Healthy Female Subjects

    Ana Cecilia Bardan-Inchaustegui1, Iris Jazmín Colunga Pedraza2, Rosa Icela Arvizu-Rivera2, Gisela Garcia-Arellano3, Griselda Serna-Peña4, Maria F. Elizondo-Benitez5, Aleydis Gonzalez Melendez2, Fernanda Massiel Garcia6 and Dionicio Galarza-Delgado7, 1Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico, 2Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, 3Hospital Universitario \"Dr. José Eleuterio González\", Monterrey, Nuevo León, Mexico, 4Hospital Universitario "Dr. José Eleuterio González", UANL, Monterrey, Mexico, 5Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, 6Hospital Universitario Dr José Eleuterio González, Monterrey, Nuevo León, Mexico, 7UANL Hospital Universitario, Monterrey, Nuevo León, Mexico

    Background/Purpose: Premenstrual dysphoric disorder (PMDD), a severe form of premenstrual syndrome, is classified as a psychiatric disorder characterized by moderate to severe physical, affective, or…
  • Abstract Number: 0471 • ACR Convergence 2024

    Understanding the Role of the Complement System in Insulin Resistance and Metabolic Syndrome in Patients with Rheumatoid Arthritis

    Jose Viotti-Serra1, Maria Garcia-Gonzalez2, Fuensanta Gomez-Bernal1, Juan Carlos Quevedo-Abeledo3, Miguel Angel Gonzalez-Gay4 and ivan Ferraz-Amaro5, 1Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain, 2Hospital Universitario de Canarias, SC Tenerife, Canarias, Spain, 3Hospital Universitario de Gran Canaria Dr Negrín, Las Palmas de GC, Canarias, Spain, 4University of Cantabria, Fundación Jimenez Díaz, Madrid, Madrid, Spain, 5Rheumatology, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain

    Background/Purpose: The complement (C) system has been associated with the etiopathogenesis of rheumatoid arthritis (RA). Insulin resistance (IR) and metabolic syndrome are prevalent among RA…
  • Abstract Number: 0488 • ACR Convergence 2024

    Association of Anti-CarP Levels with Clinical Activity and Serological Profile in Rheumatoid Arthritis

    Pablo Martínez Calabuig1, Elena Grau García2, Samuel Leal Rodriguez2, Ernesto Tovar Sugrañes3, José Ivorra-Cortés4, Carmen Riesco Barcena3, Anderson Huaylla Quispe3, Laura Mas Sánchez5, Pablo Muñoz Martínez6, Daniel Ramos Castro3, Alba Torrat noves7, Iago Alcantara Alvarez8, Belén Villanueva Mañés8, Miguel Simeo Vinaixa8, Andrés Pérez Hurtado3 and Jose A Román-Ivorra9, 1HOSPITAL GENERAL UNIVERSITARIO VALENCIA SPAIN, Ontinyent, Comunidad Valenciana, Spain, 2HUP La Fe, Valencia, Spain, 3Rheumatology Department. HUP La Fe, Valencia, Spain, 4Hospital Universitario La Fe, PALMA DE MALLORCA, Spain, 5Resident at Hospital Universitari i Politecnic La Fe, Valéncia, Spain, 6Hospital Universitario y Politècnico La Fe, Sagunto, Spain, 7Hospital Universitari i Politècnic La Fe de Valencia, Valencia, Comunidad Valenciana, Spain, 8Rheumatology Department. HUP La Fe, Valencia, Comunidad Valenciana, Spain, 9Hospital Universitari i Politècnic la Fe, Valencia, Comunidad Valenciana, Spain

    Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune disease where the presence of rheumatoid factor (RF) and anti-citrullinated peptide antibodies (antiCCP) has been associated to…
  • Abstract Number: 0505 • ACR Convergence 2024

    UseofaMolecularSignatureResponseClassifiertoPredictInadequateResponsetoTNFiResultsinFewer Patients Prescribed TNFi

    George Karpouzas1, Lixia Zhang2, Mark Zielinski2, Brian Cheng2 and Sherry Guardiano3, 1Harbor-UCLA Medical Center, Torrance, CA, 2Scipher Medicine Corporation, Waltham, MA, 3Scipher Medicine Corporation, Keene, NH

    Background/Purpose: Tumor necrosis factor inhibitors (TNFi) are generally the first class of biologic disease modifying anti-rheumatic drugs (DMARDs) prescribed for rheumatoid arthritis (RA) patients with…
  • Abstract Number: 0522 • ACR Convergence 2024

    Hematological Impact Assessment of Tofacitinib, Baricitinib, and Upadacitinib in Rheumatoid Arthritis Treatment

    Soo Min Ahn, Mi-Ra Cho, Ji Seon Oh, Yong-Gil Kim, Chang-Keun Lee, Bin Yoo and Seokchan Hong, Asan Medical Center, Seoul, Republic of Korea

    Background/Purpose: Janus kinase (JAK) inhibitors' introduction has significantly revolutionized the therapeutic landscape, notably influencing the management strategies for rheumatoid arthritis (RA). To compare the effects…
  • « Previous Page
  • 1
  • …
  • 30
  • 31
  • 32
  • 33
  • 34
  • …
  • 219
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology